Solitary fibrous tumor/hemangiopericytoma: treatment results based on the 2016 WHO classification

Restricted access


Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a new combined entity for which a soft-tissue–type grading system, ranging from grades I to III, has been introduced in the 2016 WHO classification of tumors of the CNS. The results of the treatment of this new disease entity require evaluation.


The authors retrospectively reevaluated the pathological findings and medical records of patients with SFT/HPC. This study included 60 patients (27 men and 33 women, median age 42.5 years, range 13–69 years) treated at Severance Hospital between February 1981 and February 2016. Four, 40, and 16 patients were categorized as having SFT/HPC grades I, II, and III, respectively. Among these patients, SFTs diagnosed in 7 patients were regraded as grades I (n = 4), II (n = 2), and III (n = 1).


The median overall survival (OS) was 73.2 months (range 1.4–275.7 months), and the progression-free survival (PFS) after the first operation was 53.8 months (range 1.4–217.7 months). Six patients (10%) showed extracranial metastasis during a median period of 103.7 months (range 31.9–182.3 months). Nineteen patients (31.7%) presented with tumor recurrences. The patients in the grade III group had shorter PFS and OS, as well as a shorter period to extracranial metastasis, compared with patients in the grade II group. In the grade II group, patients who underwent gross-total resection showed longer PFS than those who underwent subtotal resection; however, there was no difference in OS. Patients who underwent adjuvant radiation therapy (RT) after surgery had longer PFS compared with that of patients who did not undergo adjuvant RT.


The SFT/HPC grade I group showed a relatively benign course compared with those of the other groups. The grade III group presented a course with a more aggressive nature than that of the grade II group. In the grade II group, the extent of resection and adjuvant RT was significantly associated with longer PFS. The long-term follow-up and periodic systemic evaluation are mandatory to detect systemic metastasis.

ABBREVIATIONS EOR = extent of resection; GKS = Gamma Knife surgery; GTR = gross-total resection; HPC = hemangiopericytoma; OS = overall survival; PFS = progression-free survival; RT = radiation therapy; SFT = solitary fibrous tumor; STR = subtotal resection.

Article Information

Correspondence Jong Hee Chang: Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

INCLUDE WHEN CITING Published online March 9, 2018; DOI: 10.3171/2017.9.JNS171057.

W.S.C. and J.H.C. contributed equally to this work and share senior authorship.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

© AANS, except where prohibited by US copyright law.



  • View in gallery

    Kaplan-Meier survival curves showing a comparison of recurrence rate and OS between the GTR (n = 27) and STR (n = 13) groups in patients with WHO grade II tumors. Left: The STR group showed a statistically significant higher recurrence rate compared with the GTR group (p = 0.00, log-rank test). Right: Comparison of OS between the 2 resection groups showing no statistical significance (p = 0.315). Figure is available in color online only.

  • View in gallery

    Kaplan-Meier survival curves showing a comparison of OS and PFS between initial surgery with adjuvant RT group (n = 25) and without adjuvant RT group (n = 15) in patients with WHO grade II tumors. Left: The surgery with adjuvant RT group showed a statistically significant longer PFS compared with the surgery without adjuvant RT group (p = 0.025, log-rank test). Right: Comparison of OS between the 2 groups showed no statistical significance (p = 0.946). Figure is available in color online only.

  • View in gallery

    Kaplan-Meier survival curves showing a comparison between the WHO grade II and III groups. Left: The PFS between the 2 groups showed no statistically significant difference (p = 0.869). Right: The OS of the WHO grade III group was significantly shorter than that of the WHO grade II group (p = 0.003, log-rank test). Figure is available in color online only.

  • View in gallery

    Axial MR images from a patient in the SFT/HPC WHO grade II group. A: The patient presented with a large tumor at the right-side temporal, petrous bone, cerebellopontine angle area. B: After 107 months of initial treatment, the patient showed a fourth tumor recurrence and underwent RT. C: After the fourth recurrence and RT, the follow-up imaging showed a good treatment response state. D: After the fifth recurrence of tumor, the patient underwent a fourth GKS.



Alén JFLobato RDGómez PABoto GRLagares ARamos A: Intracranial hemangiopericytoma: study of 12 cases. Acta Neurochir (Wien) 143:5755862001


Bassiouni HAsgari SHübschen UKönig HJStolke D: Intracranial hemangiopericytoma: treatment outcomes in a consecutive series. Zentralbl Neurochir 68:1111182007


Carneiro SSScheithauer BWNascimento AGHirose TDavis DH: Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Pathol 106:2172241996


Chmielecki JCrago AMRosenberg MO’Connor RWalker SRAmbrogio L: Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45:1311322013


Choi JPark SHKhang SKSuh YLKim SPLee YS: Hemangiopericytomas in the central nervous system: a multicenter study of Korean cases with validation of the usage of STAT6 immunohistochemistry for diagnosis of disease. Ann Surg Oncol 23 (Suppl 5):9549612016


Damodaran ORobbins PKnuckey NBynevelt MWong GLee G: Primary intracranial haemangiopericytoma: comparison of survival outcomes and metastatic potential in WHO grade II and III variants. J Clin Neurosci 21:131013142014


Ecker RDMarsh WRPollock BEKurtkaya-Yapicier OMcClelland RScheithauer BW: Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patients. J Neurosurg 98:118211872003


Fargen KMOpalach KJWakefield DJacob RPYachnis ATLister JR: The central nervous system solitary fibrous tumor: a review of clinical, imaging and pathologic findings among all reported cases from 1996 to 2010. Clin Neurol Neurosurg 113:7037102011


Fletcher CDM: The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification. Histopathology 64:2112014


Fountas KNKapsalaki EKassam MFeltes CHDimopoulos VGRobinson JS: Management of intracranial meningeal hemangiopericytomas: outcome and experience. Neurosurg Rev 29:1451532006


Fritchie KJJin LRubin BPBurger PCJenkins SMBarthelmeß S: NAB2-STAT6 gene fusion in meningeal hemangiopericytoma and solitary fibrous tumor. J Neuropathol Exp Neurol 75:2632712016


Gengler CGuillou L: Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 48:63742006


Ghose AGuha GKundu RTew JChaudhary R: CNS hemangiopericytoma: a systematic review of 523 patients. Am J Clin Oncol 40:2232272017


Guthrie BLEbersold MJScheithauer BWShaw EG: Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25:5145221989


Han NKim HMin SKPaek SHPark CKChoi SH: Meningeal solitary fibrous tumors with delayed extracranial metastasis. J Pathol Transl Med 50:1131212016


Hasegawa TMatsuno YShimoda THasegawa FSano THirohashi S: Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior. Hum Pathol 30:146414731999


Insabato LSiano MSomma AGentile RSantangelo MPettinato G: Extrapleural solitary fibrous tumor: a clinicopathologic study of 19 cases. Int J Surg Pathol 17:2502542009


Kano HNiranjan AKondziolka DFlickinger JCLunsford LD: Adjuvant stereotactic radiosurgery after resection of intracranial hemangiopericytomas. Int J Radiat Oncol Biol Phys 72:133313392008


Kim BSKong DSSeol HJNam DHLee JI: Gamma knife radiosurgery for residual or recurrent intracranial hemangiopericytomas. J Clin Neurosci 35:35412017


Kim JHJung HWKim YSKim CJHwang SKPaek SH: Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol 59:47542003


Kim YJPark JHKim YIJeun SS: Treatment strategy of intracranial hemangiopericytoma. Brain Tumor Res Treat 3:68742015


Kleihues PLouis DNScheithauer BWRorke LBReifenberger GBurger PC: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:2152292002


Louis DNOhgaki HWiestler ODCavenee WKBurger PCJouvet A: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:971092007


Louis DNPerry AReifenberger Gvon Deimling AFigarella-Branger DCavenee WK: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:8038202016


Melone AGD’Elia ASantoro FSalvati MDelfini RCantore G: Intracranial hemangiopericytoma—our experience in 30 years: a series of 43 cases and review of the literature. World Neurosurg 81:5565622014


Mena HRibas JLPezeshkpour GHCowan DNParisi JE: Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 22:84911991


Noh SHLim JJCho KG: Intracranial hemangiopericytomas: a retrospective study of 15 patients with a special review of recurrence. J Korean Neurosurg Soc 58:2112162015


Ogawa KTada TTakahashi SSugiyama NInaguma STakahashi SS: Malignant solitary fibrous tumor of the meninges. Virchows Arch 444:4594642004


Osuga THayashi TIshiwatari HOno MYoshida MKimura Y: Pancreatic metastasis from a solitary fibrous tumor of the central nervous system. JOP 15:58622014


Park MSAraujo DM: New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 21:3273312009


Robinson DRWu YMKalyana-Sundaram SCao XLonigro RJSung YS: Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45:1801852013


Rutkowski MJBloch OJian BJChen CSughrue METihan T: Management of recurrent intracranial hemangiopericytoma. J Clin Neurosci 18:150015042011


Rutkowski MJJian BJBloch OChen CSughrue METihan T: Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer 118:162816362012


Rutkowski MJSughrue MEKane AJAranda DMills SABarani IJ: Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg 113:3333392010


Schiariti MGoetz PEl-Maghraby HTailor JKitchen N: Hemangiopericytoma: long-term outcome revisited. Clinical article. J Neurosurg 114:7477552011


Schweizer LKoelsche CSahm FPiro RMCapper DReuss DE: Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125:6516582013


Sonabend AMZacharia BEGoldstein HBruce SSHershman DNeugut AI: The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg 120:3003082014


Tihan TViglione MRosenblum MKOlivi ABurger PC: Solitary fibrous tumors in the central nervous system. A clinicopathologic review of 18 cases and comparison to meningeal hemangiopericytomas. Arch Pathol Lab Med 127:4324392003


Vallat-Decouvelaere AVDry SMFletcher CD: Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol 22:150115111998


Yalcin CETihan T: Solitary fibrous tumor/hemangiopericytoma dichotomy revisited: a restless family of neoplasms in the CNS. Adv Anat Pathol 23:1041112016




All Time Past Year Past 30 Days
Abstract Views 92 92 92
Full Text Views 48 48 48
PDF Downloads 61 61 61
EPUB Downloads 0 0 0


Google Scholar